ethyl N-[4-(cyclododecylamino)pyridin-3-yl]sulfonylcarbamate | 1027498-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl N-[4-(cyclododecylamino)pyridin-3-yl]sulfonylcarbamate
• CAS: 1027498-63-0
• 化学式: C₂₀H₃₃N₃O₄S
• 分子量: 411.566
• InChiKey: HSYKYMKKQHZKTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  环己胺 、 ethyl N-[4-(cyclododecylamino)pyridin-3-yl]sulfonylcarbamate 以 甲苯 为溶剂， 反应 5.0h， 生成 BM 28
  参考文献：
  名称：

  Synthesis and pharmacology of pyrid-3-yl sulfonylureas and thioureas as astrocytic Na+ 2C1− K+ cotransporter inhibitors

  摘要：

  The pharmacology of lipophilic 4-arylamino- and 4-cycloalkylaminopyrid-3-ylsulfonyl(thio)ureas and their synthesis designed from torasemide are described. These compounds could lead to a method of inhibiting the astrocytic Na+ 2Cl(-) K+ cotransporter and thus treating cerebral edema. Their lipophilicity and ionization constants were determined. Seven lipophilic compounds (17, 18, 22, 23, 24, 32 and 36) exhibited a high inhibitory potency (IC50 < 10 mu M) and had lost the diuretic properties of torasemide. One of them, N-([4-(cycloheptylamino)pyrid-3-yl]sulfonyl)-N'-cycloheptylurea 17 (0.1-1 mg/kg) was found to increase the gasp delay in hypoxia-exposed mice. In preliminary experiments, 17 (1-2.5 mg/kg) strongly reduced the morbidity and mortality rate of gerbils after permanent left carotid artery ligation. In-vitro experiments confirmed its antiedematous activity.

  DOI：

  10.1016/0223-5234(94)90145-7
• 作为产物：
  描述：

  氯甲酸乙酯 、 4-(Cyclododecylamino)pyridine-3-sulfonamide 在 吡啶 作用下， 反应 0.33h， 生成 ethyl N-[4-(cyclododecylamino)pyridin-3-yl]sulfonylcarbamate
  参考文献：
  名称：

  Synthesis and pharmacology of pyrid-3-yl sulfonylureas and thioureas as astrocytic Na+ 2C1− K+ cotransporter inhibitors

  摘要：

  The pharmacology of lipophilic 4-arylamino- and 4-cycloalkylaminopyrid-3-ylsulfonyl(thio)ureas and their synthesis designed from torasemide are described. These compounds could lead to a method of inhibiting the astrocytic Na+ 2Cl(-) K+ cotransporter and thus treating cerebral edema. Their lipophilicity and ionization constants were determined. Seven lipophilic compounds (17, 18, 22, 23, 24, 32 and 36) exhibited a high inhibitory potency (IC50 < 10 mu M) and had lost the diuretic properties of torasemide. One of them, N-([4-(cycloheptylamino)pyrid-3-yl]sulfonyl)-N'-cycloheptylurea 17 (0.1-1 mg/kg) was found to increase the gasp delay in hypoxia-exposed mice. In preliminary experiments, 17 (1-2.5 mg/kg) strongly reduced the morbidity and mortality rate of gerbils after permanent left carotid artery ligation. In-vitro experiments confirmed its antiedematous activity.

  DOI：

  10.1016/0223-5234(94)90145-7

文献信息

• Synthesis and pharmacology of pyrid-3-yl sulfonylureas and thioureas as astrocytic Na+ 2C1− K+ cotransporter inhibitors
  作者：B Masereel、P Renard、M Schynts、B Pirotte、P de Tullio、J Delarge

  DOI：10.1016/0223-5234(94)90145-7

  日期：1994.1

  The pharmacology of lipophilic 4-arylamino- and 4-cycloalkylaminopyrid-3-ylsulfonyl(thio)ureas and their synthesis designed from torasemide are described. These compounds could lead to a method of inhibiting the astrocytic Na+ 2Cl(-) K+ cotransporter and thus treating cerebral edema. Their lipophilicity and ionization constants were determined. Seven lipophilic compounds (17, 18, 22, 23, 24, 32 and 36) exhibited a high inhibitory potency (IC50 < 10 mu M) and had lost the diuretic properties of torasemide. One of them, N-([4-(cycloheptylamino)pyrid-3-yl]sulfonyl)-N'-cycloheptylurea 17 (0.1-1 mg/kg) was found to increase the gasp delay in hypoxia-exposed mice. In preliminary experiments, 17 (1-2.5 mg/kg) strongly reduced the morbidity and mortality rate of gerbils after permanent left carotid artery ligation. In-vitro experiments confirmed its antiedematous activity.